S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Adicet Bio Stock Forecast, Price & News

+0.08 (+0.55%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
288,916 shs
Average Volume
860,997 shs
Market Capitalization
$587.20 million
P/E Ratio
Dividend Yield
Price Target

Adicet Bio MarketRank™ Forecast

Analyst Rating
3.00 Rating Score
99.5% Upside
$29.29 Price Target
Short Interest
26.03% of Float Sold Short
Dividend Strength
News Sentiment
0.55mentions of Adicet Bio in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$167.56 K Sold Last Quarter
Proj. Earnings Growth
From ($0.78) to ($2.03) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.86 out of 5 stars

Medical Sector

662nd out of 1,428 stocks

Pharmaceutical Preparations Industry

325th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ACET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.

Adicet Bio logo

About Adicet Bio (NASDAQ:ACET) Stock

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

ACET Stock News Headlines

StockNews.com Downgrades Adicet Bio (NASDAQ:ACET) to Sell
Where Adicet Bio Stands With Analysts
Adicet Bio files for $500M mixed shelf offering
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Trading Companies & Distributors
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
$-62 million
Pretax Margin


Sales & Book Value

Annual Sales
$9.73 million
Book Value
$9.49 per share


Free Float
Market Cap
$587.20 million

Adicet Bio Frequently Asked Questions

Should I buy or sell Adicet Bio stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Adicet Bio stock.
View analyst ratings for Adicet Bio
or view top-rated stocks.

What is Adicet Bio's stock price forecast for 2022?

7 analysts have issued 12 month price targets for Adicet Bio's shares. Their ACET stock forecasts range from $21.00 to $34.00. On average, they anticipate Adicet Bio's stock price to reach $29.29 in the next twelve months. This suggests a possible upside of 99.5% from the stock's current price.
View analysts' price targets for Adicet Bio
or view top-rated stocks among Wall Street analysts.

How has Adicet Bio's stock price performed in 2022?

Adicet Bio's stock was trading at $17.49 on January 1st, 2022. Since then, ACET stock has decreased by 16.1% and is now trading at $14.68.
View the best growth stocks for 2022 here

When is Adicet Bio's next earnings date?

Adicet Bio is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Adicet Bio

How were Adicet Bio's earnings last quarter?

Adicet Bio, Inc. (NASDAQ:ACET) issued its earnings results on Thursday, May, 12th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.17. The company had revenue of $24.99 million for the quarter, compared to analyst estimates of $13.74 million. Adicet Bio had a negative trailing twelve-month return on equity of 13.61% and a negative net margin of 93.18%.
View Adicet Bio's earnings history

Who are Adicet Bio's key executives?

Adicet Bio's management team includes the following people:
  • Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA, CEO, Pres & Director (Age 50, Pay $866.77k) (LinkedIn Profile)
  • Dr. Aya Jakobovits Ph.D., Founder & Independent Director (Age 69, Pay $43.51k)
  • Mr. Brian Nicholas Harvey, Chief Financial Officer (Age 61, Pay $596.79k)
  • Dr. Francesco Galimi M.D., Ph.D., Chief Medical Officer & Sr. VP (Age 54, Pay $651.39k)
  • Dr. Donald Healey, Chief Technology Officer (Age 60)
  • Dr. Blake Aftab Ph.D., Sr. VP & Chief Scientific Officer

What other stocks do shareholders of Adicet Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include Marin Software (MRIN), FluoroPharma Medical (FPMI), Aurora Cannabis (ACB), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE).

What is Adicet Bio's stock symbol?

Adicet Bio trades on the NASDAQ under the ticker symbol "ACET."

How do I buy shares of Adicet Bio?

Shares of ACET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adicet Bio's stock price today?

One share of ACET stock can currently be purchased for approximately $14.68.

How much money does Adicet Bio make?

Adicet Bio (NASDAQ:ACET) has a market capitalization of $587.20 million and generates $9.73 million in revenue each year. The company earns $-62 million in net income (profit) each year or ($1.15) on an earnings per share basis.

How many employees does Adicet Bio have?

Adicet Bio employs 86 workers across the globe.

How can I contact Adicet Bio?

Adicet Bio's mailing address is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. The official website for Adicet Bio is www.aceto.com. The company can be reached via phone at (857) 315-5528 or via email at jburfening@lhai.com.

This page (NASDAQ:ACET) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.